Peptide-Based Therapies for Neurodegenerative Diseases

📖 Wiki Page

therapeutic673 wordssynced 2026-04-02

Peptide-Based Therapies for Neurodegenerative Diseases

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Peptide-Based Therapies for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Sequence/Target</td>
</tr>
<tr>
<td class="label">Brevigen</td>
<td>[Aβ42](/proteins/amyloid-beta) C-terminal</td>
</tr>
<tr>
<td class="label">CAD106</td>
<td>Aβ1-6 carrier</td>
</tr>
<tr>
<td class="label">ACI-35</td>
<td>Phospho-[tau](/proteins/tau) liposome</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Davunetide</td>
<td>NAP/tau</td>
</tr>
<tr>
<td class="label">Peptide 5</td>
<td>[α-synuclein](/proteins/alpha-synuclein)</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Peptide</td>
</tr>
<tr>
<td class="label">NCT04637438</td>
<td>Lu AF20513</td>
</tr>
<tr>
<td class="label">NCT04562870</td>
<td>davunetide</td>
</tr>
<tr>
<td class="label">NCT05413317</td>
<td>peptide X</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Reason</td>
</tr>
<tr>
<td class="label">Brevigen</td>
<td>Insufficient efficacy</td>
</tr>
<tr>
<td class="label">Bapineuzumab</td>
<td>ARIA, no cognitive benefit</td>
</tr>
<tr>
<td class="label">Semaglintide</td>
<td>BBB penetration issues</td>
</tr>
</table>

Introduction

...

Peptide-Based Therapies for Neurodegenerative Diseases

Introduction

Peptide Based Therapies For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Mermaid diagram (expand to render)

Peptides are short chains of amino acids (typically 2-50 residues) that can:

Mimic or block protein-protein interactions
Cross cell membranes with appropriate design
Target specific protein aggregates
Modulate receptor function

Approved Peptide Therapies

Alzheimer's Disease

Parkinson's Disease

Peptide Classes

1. Aggregation Inhibitors

Mechanism: Bind to misfolded proteins, preventing oligomerization and fibril formation.

Examples:

[Aβ](/proteins/amyloid-beta) aggregation inhibitors: Peptides targeting Aβ42 hydrophobic regions[@inhibitors2021]
α-synuclein inhibitors: Peptide fragments mimicking N-terminal region[@computing2020]
[Tau](/proteins/tau) aggregation inhibitors: PHF6 motif peptides[@tau2019]

Challenges: [Blood-brain barrier](/entities/blood-brain-barrier) penetration, stability, delivery.

2. Neuroprotective Peptides

Mechanism: Promote neuronal survival, reduce [apoptosis](/entities/apoptosis), support synaptic function.

Examples:

BDNF-mimetic peptides: Activate TrkB signaling[@bdnf2018]
GDNF-mimetic peptides: Support dopaminergic [neurons](/entities/neurons)[@gdnf2017]
NAP (Davunetide): Microtubule stabilization[@nap2016]

3. Cell-Penetrating Peptides (CPPs)

Mechanism: Cross cell membranes, deliver cargo to intracellular targets.

Examples:

TAT fusion proteins: Deliver therapeutic proteins[@tat2020]
Penetratin: CNS delivery platform[@penetratin2019]
Arginine-rich peptides: Efficient cellular uptake[@arginine2021]

4. Antimicrobial Peptides (AMPs)

Mechanism: Native defense peptides with neuroprotective properties.

Examples:

LL-37: Neuroinflammation modulation[@ref2018]
Defensins: Microglial activation regulation[@defensins2019]

Research Directions

Stapled Peptides

Helix stabilization increases stability
Improved BBB penetration
Enhanced target affinity[@stapled2020]

Cyclic Peptides

Proteolytic stability
Reduced clearance
Constrained conformations[@cyclic2021]

Peptide-Drug Conjugates

Targeted delivery
Controlled release
Combination therapy[@conjugates2022]

Clinical Trials

Active Trials

Failed Trials

Manufacturing

Challenges

Scalable synthesis
Purification protocols
Formulation stability
Cost of goods

Advances

Solid-phase peptide synthesis
Microwave-assisted synthesis
Flow chemistry
Recombinant expression

Future Perspectives

Emerging Technologies

Computational design: AI-guided peptide optimization
Self-assembling peptides: Sustained release depots
Peptide arrays: Personalized medicine approaches
Hybrid molecules: Peptide-small molecule chimeras

Combination Approaches

Peptide + small molecule
Peptide + antibody
Peptide + cell therapy
Peptide + gene therapy

Background

The study of Peptide Based Therapies For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

[ClinicalTrials.gov Peptide Search](https://clinicaltrials.gov)
[Peptide Science Journal](https://www.mdpi.com/journal/peptides)
[International Society for Peptide Science](https://www.ipspeptidescience.org)

References

Unknown, Aβ Aggregation (2020) (2020)

Unknown, CAD106 (2019) (2019)

Unknown, ACI-35 (2021) (2021)

Gozes et al, (2015) (2015)

Unknown, α-synuclein peptides (2022) (2022)

Unknown, Aβ inhibitors (2021) (2021)

Unknown, Computing approaches (2020) (2020)

Unknown, Tau aggregation (2019) (2019)

Unknown, BDNF mimetics (2018) (2018)

Unknown, GDNF analogs (2017) (2017)

Unknown, NAP (2016) (2016)

Unknown, TAT delivery (2020) (2020)

Unknown, Penetratin (2019) (2019)

Unknown, Arginine peptides (2021) (2021)

Unknown, LL-37 (2018) (2018)

Unknown, Defensins (2019) (2019)

Unknown, Stapled peptides (2020) (2020)

Unknown, Cyclic peptides (2021) (2021)

Unknown, Conjugates (2022) (2022)

📖 View canonical wiki page →

Peptide-Based Therapies for Neurodegenerative Diseases

Peptide-Based Therapies for Neurodegenerative Diseases

Introduction

Peptide-Based Therapies for Neurodegenerative Diseases

Introduction

Overview

Approved Peptide Therapies

Alzheimer's Disease

Parkinson's Disease

Peptide Classes

1. Aggregation Inhibitors

2. Neuroprotective Peptides

3. Cell-Penetrating Peptides (CPPs)

4. Antimicrobial Peptides (AMPs)

Research Directions

Stapled Peptides

Cyclic Peptides

Peptide-Drug Conjugates

Clinical Trials

Active Trials

Failed Trials

Manufacturing

Challenges

Advances

Future Perspectives

Emerging Technologies

Combination Approaches

Background

See Also

External Links

References